Abstract: Systems, methods, and apparatuses for utilizing heat are provided. A heat pump is configured to provide high-pressure steam and includes at least one compressor and at least one flash vessel. A heat exchanger is configured to be disposed proximate to a facility and further includes a first flow path and the second flow path. The first flow path is configured to transfer heat to the second flow path within the heat exchanger. An inlet of the first flow path is configured to be coupled to a source of hot fluid exiting the facility. Moreover, an inlet of the second flow path is configured to be coupled to a water source. An outlet of the second flow path is configured to be coupled to an inlet of the heat pump.

Abstract: Systems, methods, and apparatuses for producing high-pressure steam are provided. A compressor train includes a series of at least two compressors, an inlet of the compressor train, and an outlet of the compressor train. The outlet of the compressor train is configured to provide high-pressure steam to a facility. A flash vessel train includes a series of at least two flash vessels. The series of at least two flash vessels includes a terminal flash vessel at one end of the flash vessel train. Furthermore, a vapor outlet of the terminal flash vessel is fluidly coupled to the inlet of the compressor train. Additionally, vapor outlets of a remainder of the series of at least two flash vessels are fluidly coupled between compressors of the series of at least two compressors.

Abstract: The present application discloses method and sewer (111) for detecting faults associated with a gas chromatograph device (100) in a process plant. The gas chromatograph device (100) is associated with a database (110) configured to store a measured chromatogram, and historic chromatograms. Initially, the server receives the measured chromatogram from the database. Upon receiving the measured chromatogram, the server is configured to detect at least one real-time symptom for measured chromatogram. The real-time symptoms may be detected by comparing the historic chromatograms with predetermined configuration data to the measured chromatogram. Upon detecting the real-time symptoms, the server is configured to determine faults associated with the gas chromatograph device. The faults are determined by mapping the real-time symptoms and fault signature data received from the database.

Abstract: A system for classifying to apply for a microloan by a user is provided. The system includes user device associated with a user, and loan applying user classification system. The loan applying user classification system 106 collects raw data from at least one of (i) one or more programs on the user device directly; (ii) the one or more programs indirectly through the network or (iii) both. The raw data includes mobile brand, screen height, demographic details, mcc, session timestamp, sessionid, session duration, etc. The loan applying user classification system is configured to (i) pre-process the raw data to obtain pre-processed data; (ii) identify representative set of features (i.e. training dataset) from the pre-processed data; (iii) balance an imbalanced training dataset to obtain balanced dataset; and (iv) generate a classification model using balanced dataset to classify in applying for micro-loan by the user.

Abstract: The present application discloses method and sewer (111) for detecting faults associated with a gas chromatograph device (100) in a process plant. The gas chromatograph device (100) is associated with a database (110) configured to store a measured chromatogram, and historic chromatograms. Initially, the server receives the measured chromatogram from the database. Upon receiving the measured chromatogram, the server is configured to detect at least one real-time symptom for measured chromatogram. The real-time symptoms may be detected by comparing the historic chromatograms with predetermined configuration data to the measured chromatogram. Upon detecting the real-time symptoms, the server is configured to determine faults associated with the gas chromatograph device. The faults are determined by mapping the real-time symptoms and fault signature data received from the database.

Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Described are ROR? modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Described are ROR? modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

Abstract: A MEMS electrostatic actuator includes a bottom plate affixed to a substrate and a top plate suspended above the bottom plate. The top plate has a parallel plate center section and two rotating members electrically connected to the center section. Each rotating member is attached centrally of the rotating member for rotation about an axis of rotation to a set of anchor posts. The attachment includes at least one pair of torsional springs attached along each axis, each spring comprising a rectangular metal square that twists as the rotational members rotate. Electrostatic pull-down electrodes are underneath each rotational member.

Abstract: A MEMS mixer filter including an array of a multiplicity of resonator elements with conductive outer surfaces in a coplanar rectangularly tiled array, and two sets of DC bias lines in which alternating resonator elements in each row and column are connected to one or the other sets of bias lines so that laterally adjacent resonators may be biased to a DC potential. The resonator elements are uniform in size and shape. Lateral dimensions of the resonator elements are between 5 and 50 microns. The resonator elements are between 100 nanometers and 100 microns thick, and adjacent resonator elements are separated by a gap between 100 and 500 nanometers. A process of forming the MEMS mixer filter.

Abstract: A MEMS electrostatic actuator includes a bottom plate affixed to a substrate and a top plate suspended above the bottom plate. The top plate has a parallel plate center section and two rotating members electrically connected to the center section. Each rotating member is attached centrally of the rotating member for rotation about an axis of rotation to a set of anchor posts. The attachment includes at least one pair of torsional springs attached along each axis, each spring comprising a rectangular metal square that twists as the rotational members rotate. Electrostatic pull-down electrodes are underneath each rotational member.

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

Abstract: A polishing head is presented. The polishing head includes a housing having top and bottom surfaces. The housing is formed from a single piece of material. The polishing head includes grooves disposed on the bottom surface and an inlet in communication with the grooves for coupling to a pressure medium supply to supply a pressure medium to the grooves. The pressure medium when supplied to the grooves exerts pressure on a template when attached to the bottom surface to provide back side pressure on a back surface of an article when temporally attached to the template.

Abstract: The present invention relates to an improved process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride of Formula I.